A new experimental treatment has demonstrated its effectiveness in the destruction of brain tumors



A new study of scientists at the US Cancer Center Massey VCU showed that an experimental drug known as AZ32 leads to selective sensitization of brain tumors and radiation, and significantly increases the chances of Survival of mice used in experiments with glioblastoma, a more common and lethal form of cancer in humans.

Published in the Molecular Cancer Therapeutics Magazine, the study comes as a complement to the research of principal author Kristoffer Valerie and opens the way to the first phase of clinical trials where a more effective substance, AZ1390, will be used in A combination of X-ray therapy to treat cancer in the brain. An accompanying study of AZ1390 was recently published in the advances of science.

Our New YouTube Video


Please subscribe to our youtube channel BHASKBAN


Video Embed by :Bhaskban


 "Our study is the first to show that an inhibitor like AZ32 can be administered orally and penetrate the blood-brain barrier and can create radiation sensitivity in cancer cells," Valerie said.

The study established the basis for the first phase of clinical trials conducted by ASTRAZENECA, which would test AZ1390 in combination with radiotherapy to treat tumors in the brain. The safety and tolerability of AZ1390 augmentation doses will be established in combination with various tumor therapies, according to physician Xpress.

Powered by Blogger.